Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants
This study aims to evaluate the associations between switching from warfarin to non-vitamin K oral anticoagulants (NOACs), exposure to potential drug-drug interactions (DDIs), and major bleeding events in working-age adults with atrial fibrillation (AF).
We conducted a retrospective cohort study using the claims database of commercially insured working-age adults with AF from 2010 to 2015. Switchers were defined as patients who switched from warfarin to NOAC; non-switchers were defined as those who remained on warfarin. We developed novel methods to calculate the number and proportion of days with potential DDIs with NOAC/warfarin. Multivariate logistic regressions were utilized to evaluate the associations between switching to NOACs, exposure to potential DDIs, and major bleeding events.
Among a total of 4126 patients with AF, we found a significantly lower number of potential DDIs and the average proportion of days with potential DDIs in switchers than non-switchers. The number of potential DDIs (AOR 1.14, 95% CI 1.02–1.27) and the HAS-BLED score (AOR 1.64, 95% CI 1.48–1.82) were significantly and positively associated with the likelihood of a major bleeding event. The proportion of days with potential DDIs was also significantly and positively associated with risk for bleeding (AOR 1.42, 95% CI 1.03, 1.96). We did not find significant associations between switching to NOACs and major bleeding events.
The number and duration of potential DDIs and patients’ comorbidity burden are important factors to consider in the management of bleeding risk in working-age AF adults who take oral anticoagulants.
KeywordsDrug-drug interactions Atrial fibrillation Bleeding Switching Non-vitamin K oral anticoagulants
We used an adjudicated claims database of commercially insured individuals, which is made available through a license to IQVIA’s Real World Data: Adjudicated Claims - US (also known as PharMetrics Plus), 10% sample. All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA or any of its affiliated or subsidiary entities.
The study was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number U54GM104942.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of West Virginia University’s Institutional Review Board (IRB) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 3.January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.CrossRefGoogle Scholar
- 4.U.S. Food & Drug administration (FDA). Drugs@FDA: FDA approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 21 August 2018.Google Scholar
- 7.Glasheen JJ, Fugit RV. How warfarin interacts with common antibiotics. Emerg Med. 2004;36:30C-I.Google Scholar
- 16.Adeboyeje G, Sylwestrzak G, White J, Rosenberg A, Abarca J, Crawford G, et al. Comparative effectiveness and safety of anticoagulant therapy with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2016;9:A2.CrossRefGoogle Scholar
- 20.IBM Micromedex® Drug Interaction Checking (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. 2018. http://www.micromedexsolutions.com/ Accessed 21 August 2018.
- 21.Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Springfield, VA: Pharmacy Quality Alliance. 2012. http://ep.yimg.com/ty/cdn/epill/pdcmpr.pdf Accessed 21 August 2018.
- 23.Liaw A, Wiener M. Classification and regression by randomForest. R news. 2002;2:18–22.Google Scholar